Member Companies

Accelerator Technologies AG (AT) was founded in 2015 as a joint initiative between the Paul Scherrer Institute PSI and a range of industry partners. The in the aim of AT is to commercialize the PSI’s leading know-how concerning accelerators, experimentation, and large facilities, as well as the institute’s outstanding application expertise regarding particle beams and photons in the areas of science, research, and industrial processes.

ANAXAM is a technology transfer center focused on applied materials analytics using neutron and synchrotron radiation. Our analytics go far beyond what is known at laboratory scale. We provide industry access to state-of-the-art material analytics originally developed for basic research, but now made available to address industrial challenges. We are a one-stop-shop for consultancy, measurements, analysis and interpretation of results, such that industry profits from the most advanced analytical techniques in the fields of imaging, diffraction and spectroscopy to solve their industrial problems.

Datalystica is a spin-off of the laboratory of atmospheric chemistry (LAC) at the Paul Scherrer Institute PSI. The company offers fast software solutions for factor analytic problems on multivariate data, any kind of data. The main product is an extremely user-friendly and powerful software package called the Source Finder (SoFi).

ELDICO SCIENTIFIC AG (The Electron Diffraction Company) is a Swiss deep-tech company founded in 2019. ELDICO develops, manufactures and markets electron diffractometers (ED) for compound analysis, enabling industrial and scientific researchers to characterize previously unmeasurable nanocrystalline systems where conventional methods (X-ray) fail. Eldico's electron diffractometers enable studies of nanocrystalline systems at least 1 million times smaller in volume. This allows hundreds of thousands of known, but not fully characterized, solids to be rapidly analyzed for commercial potential. The Eldico technology is a disruptive innovation that will help triple the number of drug candidates. It can help the pharmaceutical industry accelerate the drug discovery process and also open up fascinating new commercial prospects for the agrochemical, chemical and materials industries.

Expose GmbH is a spin-off company of the Paul Scherrer Institute PSI founded in 2008. The company offers services in protein crystallography to pharmaceutical and biotechnological companies providing fast and affordable access to synchrotron beamtime at the Swiss Light Source (SLS) and its expertise in data processing and protein structure solution.

Excelsus is a spin-off company of the Paul Scherrer Institute PSI. It offers fast, easy, and affordable access to state-of-the-art characterization tools for the structural and microstructural analysis of materials (pharmaceuticals, food and aroma compounds, pigments, polymers, and various other chemicals) for selecting, developing and manufacturing high-quality products.

GratXray, a high-tech spin-off of the PSI and ETH Zurich, is developing, producing, and commercializing a grating interferometry-based breast computed tomography (GIBCT) system. Their technology allows for more precise breast cancer imaging. It will significantly reduce the number of false positives and improve patients’ comfort during the procedure.

InterAx is uniquely positioned to assist GPCR drug candidate design and selection by integrating bioanalytical and computational pharmacology on collaborative projects with biotech and pharma companies. InterAx applies mathematical models and simulations to in-house-derived bioanalytical data to address the complexity of drug-induced cellular signaling mechanisms. The company's goal is to close the gap between laboratory experiments and in vivo studies by streamlining the critical processes of drug candidate design and selection, thereby significantly reducing the risks, costs and duration of drug discovery and the development of new drugs.

Specializing in the development and optimization of pharmaceutically active substances, leadXpro AG applies research from the Paul Scherrer Institute PSI in the field of membrane proteins, as well as world-leading technologies to investigate protein structures. The new large research facility at the PSI, the SwissFEL (launched in 2016), also offers excellent potential for this close collaboration.

Molecular Modeling Laboratory (MML) applies high-throughput quantum chemical modeling, Artificial Intelligence (AI) heuristics, and state-of-the-art electron microscopy to the study and development of life science immunointerventions and drug design. Quantum Immunology, MML’s flagship initiative, addresses how quantum mechanics translate into receptor-antigen triggering and how this knowledge may be applied to the therapy of infectious diseases, immune disorders, neurological conditions and aging. MML also combines theoretical modeling and Electron Energy Loss Spectroscopy (EELS) to optimize drug design by detecting new polymorphic crystal structures and analyzing pharmaceutical Amorphous Solid Dispersion (ASD) dynamics.

Qnami is a VC-backed high-tech company with its roots in the Physics Department of the University of Basel. It develops fundamental new technology using quantum mechanics. The control of the state of a single electron enables measurement with a precision that could never be achieved before. The technique is called quantum sensing and Qnami is enthusiastically developing it to improve people’s lives and the world. Extensive academic research and deep knowledge build the ground for all that Qnami does. With this technology, Qnami is redefining the common understanding of precision.

SenSiC focuses on the development, manufacturing and marketing of devices and systems in the field of radiation and process monitoring, in particular sensors made of Silicon Carbide (SiC).

TERAPET's vision is to develop innovative solutions that will become an integral part of the next generation of proton therapy for cancer patients, thereby rendering the therapy safer, more precise, faster and available to the wider public.

TLD Photonics designs and manufactures high-end Lasers and optical systems for industry and research. Our strong ties to leading swiss universities allow us to develop groundbreaking products and through the extensive industrial experience of our team, we ensure that the real-world applications remain at the core our developments. Our vision is to offer our customers cutting edge solutions for every element of industrial laser applications.   

XRnanotech, the leading Swiss manufacturer of nanostructured optics. 

The high-tech spin-off develops nanostructured optics for scientific research, engineering, and medical applications. XRnanotech's goal is to bring breakthrough innovations in this technology field to the market. For example, the innovative spin-off addresses the global need for advanced X-ray optics in microscopy and is committed to using its knowledge and innovation to make the nanoworld visible.

Swiss Terahertz is a start-up whose unique terahertz technologies are among the most advanced of those developed at SwissFEL in the field of terahertz radiation. The company focuses on research, development, and production of terahertz systems and highly efficient nonlinear organic crystals. Swiss Terahertz products can be integrated into specialised research infrastructures as well as into commercial spectrometers for safety-related testing, pharmaceutical testing, and non-destructive quality control.

condenZero was founded 2019 as a spin-off company of the Laboratory for Quantum Matter Research of the University of Zurich in Switzerland. Our field of expertise includes the development and production of scientific instruments and components for research applications in ultra-high vacuum and cryogenic conditions.

VDL ETG is a contract manufacturing and assembly partner that offers its customers modules, subsystems, and integrated systems. The Swiss subsidiary has a very broad portfolio and a wide range of competencies, mainly related to the high-tech vacuum technology industry.

VDL ETGs parent company, VDL Groep, headquartered in Eindhoven, the Netherlands, is an international industrial family business with more than 100 operating companies, spread throughout 19 countries, with over 15,000 employees. The activities of the VDL companies can be summarised in the “five worlds of VDL”: Science Technology & Health, Mobility, Energy & Sustainability, Infratech, and Foodtech. 

ASTRA Therapeutics is a rational drug design and development company with the mission to address unmet medical needs by delivering precision anti-pathogen cures. Eukaryotic pathogens cause a wide range of infections in humans, animals, and plants. The impact of those Eukaryotic Pathogens is vast, leading to debilitating diseases, crop damage, and economic losses.